Chong Kun Dang Pharmaceutical Corp. Overview
Chong Kun Dang is Korea's third-largest traditional pharmaceutical company by 2025 revenue (KRW 1.69 trillion), behind Yuhan and GC Biopharma and ahead of Kwangdong, Daewoong and Hanmi. Its business model combines a large domestic prescription-drug sales force with a portfolio of in-house branded generics and incrementally modified drugs, a handful of domestically discovered new chemical entities, and a heavy and growing book of in-licensed and co-promoted multinational products — currently led by Novo Nordisk's obesity drug Wegovy, Amgen's Prolia and Evenity, MSD's Januvia family and Atozet, and Bayer's Eylia. The company is attempting a strategic pivot from "best-in-Korea commercial partner" to "global innovator", underpinned by the 2023 out-licensing of HDAC6 inhibitor CKD-510 to Novartis (up to USD 1.305 billion), a first-in-house ADC (CKD-703) in US Phase 1/2a, a new NRDO subsidiary (Achella), and a planned KRW 2.2 trillion bio-research complex in Siheung-Baegot. Margins have compressed sharply as low-margin merchandise grows.
What the company does
Chong Kun Dang develops, manufactures, imports and markets human pharmaceuticals, overwhelmingly for the South Korean market. Its revenue is drawn from three sources that management and Korean sell-side analysts track separately:
-
Own products (제품) — drugs manufactured by the company, including branded generics, fixed-dose combinations and incrementally modified drugs (e.g., Telminuvo), Korean-origin new drugs (e.g., Duvie/lobeglitazone; Camtobell/belotecan), biosimilars (e.g., Nesbell/darbepoetin alfa) and OTC brands (e.g., Penzal).
-
Merchandise (상품) — finished products bought from licensors or partners and resold, and products co-promoted with multinational and domestic companies (Wegovy, Prolia, Evenity, Januvia/Janumet, Atozet, Prevenar, Eylia, Godex, Dilatrend, Fexuclue, Gliatilin under licence from Italfarmaco).
-
Licensing and milestone income — technology-transfer revenues, most visibly the USD 80 million upfront payment from Novartis for CKD-510 recognised in FY2023 and a development milestone received in May 2025.
Business and revenue model
The company is fundamentally a product-sales business (prescription and OTC drug sales to hospitals, clinics, wholesalers and pharmacies) supplemented by episodic licensing income. It has no subscription or service revenue of note. Its competitive engine is a nationwide medical-representative network with deep coverage of primary-care clinics in cardiometabolic disease (hypertension, dyslipidaemia, diabetes), which multinational originators rent through co-promotion contracts. This explains the most important structural fact about Chong Kun Dang's P&L: as co-promoted merchandise grows, revenue rises but gross margin falls, because the company books the gross sale while keeping only a distribution/promotion margin.
The dynamic is visible in the numbers. Gross margin was 39.7% in FY2023 (boosted by the Novartis upfront), 33.6% in FY2024 and 31.1% in FY2025, and Korean press reports a cost-of-sales ratio in the low-70% range in Q2 2026 versus the high-60% range a year earlier (Money Today, 5 Aug 2026; Dailian, 31 Jul 2026). A 2026 Korea Ratings analyst comment (via New Daily, 6 Jul 2026) characterised the expected trajectory as sustained top-line growth from new co-promotions (Wegovy, Godex, Fexuclue) but profitability below 2023–2025 levels because of the rising merchandise mix.
Value-chain position
Chong Kun Dang is vertically integrated across formulation development, finished-dosage manufacturing (principally at its Cheonan plant), regulatory affairs and domestic commercialisation. Active pharmaceutical ingredients are largely sourced externally or from sister companies (Chong Kun Dang Bio and Kyongbo Pharm, both controlled by Chong Kun Dang Holdings, not by the listed company). Discovery research is conducted at the Hyojong Research Institute in Yongin, Gyeonggi Province. In licensing deals the company acts as an early-to-mid-stage originator (CKD-510 was out-licensed after Phase 1) rather than a late-stage global developer.
Customers and end-markets
Customers are Korean hospitals (tertiary, general), primary-care clinics, pharmacies and pharmaceutical wholesalers, with reimbursement determined by the National Health Insurance Service (NHIS) and Health Insurance Review & Assessment Service (HIRA). End-markets by therapy: cardiovascular/metabolic (the core franchise), obesity (Wegovy since Oct 2025), bone health (Prolia, Evenity), CNS/cognition (Gliatilin), vaccines (Prevenar), ophthalmology (Eylia, from Dec 2025), hepatology (Godex), gastroenterology (Fexuclue), oncology and transplant/immunology. Exports and overseas sales are small; a geographic split was not found in the sources reviewed.
Company self-description vs independent characterisation
Company framing (paraphrased from the March 2026 AGM address by CEO Kim Young-joo): the company sustained growth through its established and newly introduced products, accepted lower profit in exchange for higher R&D investment, and will pursue "substantive" profit growth in 2026 through timely launches, product competitiveness and market responsiveness, while using the NRDO subsidiary Achella to raise R&D efficiency and building the Baegot bio complex to reach global-level bio capability (Dailypharm and Medifonews, 26 Mar 2026).
Independent characterisation: Chong Kun Dang today is best understood as a high-revenue, low-margin domestic commercial platform with an option on a small number of global R&D assets. Roughly a third of revenue appears to come from the top handful of in-licensed brands; Wegovy alone was the company's largest product in Q1 2026 at about KRW 48.8 billion (New Daily, 6 Jul 2026), around 11% of standalone quarterly sales. Organic own-brand growth is modest and under regulatory pressure (choline alfoscerate re-evaluation; the August 2026 generic price reform). The equity story therefore rests on (a) Novartis's progress with CKD-510 in atrial fibrillation, (b) CKD-703's early clinical data, and (c) management's ability to fund a KRW 2.2 trillion research complex without impairing a balance sheet that has moved from net cash to modest net debt.
Strategy
Stated strategic themes (paraphrased; FY2024–FY2025 AGMs and disclosures)
-
From sales company to innovator: shift the centre of gravity from co-promoted products to proprietary drugs, focusing on first-in-class and unmet-need medicines.
-
Platform breadth: build in-house platforms beyond small molecules — ADCs, antibodies, and cell and gene therapy (Mar 2025 AGM).
-
R&D operating model: a "three-pillar" structure — the parent focuses on discovery and biologics research plus CKD-510/CKD-703; Achella (NRDO) runs clinical development and commercialisation of transferred assets; Neurateon handles formulation and technology research.
-
Infrastructure: Siheung-Baegot bio complex to give the company end-to-end biologics R&D and process-validation capability.
-
Near-term earnings defence: timely launches, product competitiveness and diversified co-promotion contracts (ten sales/distribution contracts signed after the K-CAB exit, per Dailypharm Sep 2025).
Initiatives in the last 24 months
| Initiative | Date | Detail |
|---|---|---|
| Baegot site selection and MOU | Feb–Jun 2025 | Preferred bidder; MOU and land contract with Siheung City; KRW 2.2 tn plan |
| Exchangeable bond for Baegot | 30 Sep 2025 | KRW 61.1 bn private EB exchangeable into 626,712 treasury shares at KRW 97,500 (exchange window Nov 2025–Sep 2030); proceeds earmarked for Baegot |
| Wegovy partnership | Sep 2025 | Entry into obesity |
| Achella NRDO | Oct 2025 | Spin-out of CKD-508, CKD-514, CKD-513 |
| Eylia partnership | Dec 2025 | Entry into retinal disease |
| Woori Bank framework | May 2026 | KRW 1 tn financial support over five years |
| Baegot facility investment | Jun 2026 | KRW 392.5 bn through Aug 2028 |
| Neurateon | 2,026 | R&D technology subsidiary |
| CKD339 Phase 3 | Jul 2026 | Late-stage domestic cardiovascular asset |
Guidance and targets
Chong Kun Dang does not publish formal numeric guidance. Management's qualitative 2026 objective is profit growth after two years of decline. Sell-side expectations imply FY2026 standalone revenue of ~KRW 1.90 tn and flat operating income of ~KRW 79.5 bn, with growth of 3% or less in operating profit according to a Money Today summary of broker views (Aug 2026).
Products & Services
Major in-licensed / co-promoted products (merchandise)
| Product (INN) | Partner / originator | Therapy area | Description and status | Latest disclosed sales |
|---|---|---|---|---|
| Wegovy (semaglutide 2.4 mg) | Novo Nordisk Korea | Obesity | Once-weekly GLP-1 RA injection; Korean launch Oct 2024; co-promotion with CKD from 1 Oct 2025 to hospitals and clinics. Korea's #1 Rx product by sales in Q2 2025 (IQVIA, per Kukinews) | ~KRW 48.8 bn in Q1 2026 (company's #1 product); ~KRW 45 bn est. Q2 2026; ~KRW 190 bn est. FY2026 |
| Prolia (denosumab) | Amgen Korea | Osteoporosis | Twice-yearly RANKL antibody; patent expired Apr 2025, triggering price cuts | ~KRW 30.0 bn in Q1 2026 (-33.3% YoY) |
| Evenity (romosozumab) | Amgen Korea | Osteoporosis | Sclerostin antibody; cited as a key Q2 2026 growth driver | — |
| Januvia / Janumet / Janumet XR (sitagliptin ± metformin) | MSD | Type 2 diabetes | DPP-4 inhibitor franchise, with CKD since 2016; generics have eroded sales since 2023–24 | K-CAB plus Januvia were ~15.2% of FY2023 sales; declining |
| Atozet (ezetimibe/atorvastatin) | MSD | Dyslipidaemia | Fixed-dose combination; one of the top three products | KRW 102.7 bn FY2024; KRW 108.8–111.3 bn FY2025E |
| Vytorin (ezetimibe/simvastatin) | MSD | Dyslipidaemia | Mature combination | — |
| Prevenar 13 (pneumococcal conjugate vaccine) | Pfizer | Vaccines | Long-running distribution; cited as solid in Q2 2026 | Not disclosed for 2025–26 |
| Eylia (aflibercept) | Bayer Korea | Ophthalmology (nAMD etc.) | Anti-VEGF; agreement Dec 2025; meaningful contributor from H1 2026 | — |
| Godex (biphenyl dimethyl dicarboxylate/carnitine combination) | Celltrion Pharm | Liver disease | Co-promotion since Jan 2024 | ~4% of Q2 2026 sales (Butler.works) |
| Dilatrend / Dilatrend SR (carvedilol) | Celltrion Pharm | Hypertension / heart failure | Co-promotion since Jan 2024 | KRW 67.0 bn FY2024 |
| Fexuclue (fexuprazan) | Daewoong Pharmaceutical | GERD | P-CAB co-marketing since 2024 (K-CAB replacement); DS projected ~6.3% market share | — |
| Gliatilin (choline alfoscerate) | Italfarmaco (licensor) | Cognitive impairment / dementia | Market #2 choline brand; selective reimbursement (higher co-pay) from Oct 2025; clinical re-evaluation results submitted Jun 2026 | KRW 92.9 bn FY2024; ~KRW 14.8 bn Q1 2026 (-29.3% YoY), partly reserved against refund liability |
Sources: Kiwoom (Oct 2025), Yuanta (Jul 2025), DS Investment (26 May 2026), New Daily (6 Jul 2026), Money Today (5 Aug 2026), Bizwatch (31 Jul 2026), Dealsite (31 Jul 2026).
Discontinued: K-CAB (tegoprazan, HK inno.N) — co-promotion ended Dec 2023; about KRW 140 bn of annual sales lost (Eugene, Mar 2024).
Own products (selected; detailed specifications are on the company website)
| Product | Type | Therapy area | Notes |
|---|---|---|---|
| Telminuvo (telmisartan/S-amlodipine) | Incrementally modified FDC | Hypertension | KRW 41.7 bn FY2022 (Hanwha); later figures not disclosed |
| Duvie / Duvimet (lobeglitazone ± metformin) | Korean new drug (TZD) | Type 2 diabetes | Licensed for the US per CEO statement (Nov 2023); partner not named in sources |
| Camtobell (belotecan) † | Korean new drug | Oncology (topoisomerase I inhibitor) | Launched 2000s |
| Nesbell (darbepoetin alfa) † | Biosimilar | Renal anaemia | Out-licensed for Japan |
| Lucentis biosimilar (CKD-701) † | Biosimilar | Ophthalmology | Approved in Korea (2022) |
| Immoten | Branded product | Osteoarthritis | Cited as a growing own product in 2016 |
| Cyclosporine / tacrolimus brands † | Branded generics | Transplant | Long-established franchise |
| Penzal | OTC | Analgesic | Flagship OTC brand |
Pricing: drug prices are set by NHIS/HIRA reimbursement listing; product-level prices are not disclosed by the company. The 1 Aug 2026 drug price reform cuts prices of already-listed generics, affecting own-brand generics (Kiwoom, Jul 2026; Dailypharm headlines).
Pipeline (development products)
| Code | Mechanism / modality | Indication | Stage (Oct 2026) | Owner |
|---|---|---|---|---|
| CKD-510 (Novartis: PKN605) | Selective HDAC6 inhibitor, non-hydroxamic acid platform | Atrial fibrillation (lead); originally Charcot-Marie-Tooth | Phase 2 by Novartis (NCT07217067, started Oct 2025); listed in Novartis's CRM Phase 2 pipeline | Novartis (ex-Korea) |
| CKD-703 | c-Met antibody-drug conjugate (in-house antibody + Synaffix platform, MMAE payload) | NSCLC and solid tumours | Phase 1/2a (FDA IND Jul 2025, MFDS IND Feb 2026, first patient Apr 2026; 12 sites Korea/US) | Chong Kun Dang |
| CKD-702 | EGFR/c-Met bispecific antibody | NSCLC | Phase 1 (second part) | Chong Kun Dang |
| CKD-508 / ACL-508 | CETP inhibitor | Dyslipidaemia | Phase 1 (UK earlier; US Phase 1 started 2024–25) | Achella |
| CKD-514 | Oral GLP-1 class small molecule | Obesity / metabolic | Preclinical/early | Achella |
| CKD-513 | BBB-penetrant HDAC6 inhibitor | Neurodegenerative disease | Preclinical (data presented Jun 2026) | Achella |
| CKD-339 | Undisclosed | Hypertension | Phase 3 IND approved by MFDS (Jul 2026) | Chong Kun Dang |
| Cell & gene therapy, further ADCs | Platform | Various | Discovery | Chong Kun Dang |
Financial Narrative
All figures KRW billion, consolidated, FY ending 31 Dec. Source: S&P/StockAnalysis unless noted; EBITDA from Paasa (S&P-based); EPS split-adjusted as reported by Paasa.
Income statement
Revenue CAGR FY2021–FY2025: 5.9% (KRW 1,343.6 bn → 1,692.4 bn).
Commentary. The five-year record has three phases. FY2021–22 was steady growth driven by co-promoted cardiometabolic brands and K-CAB, with heavy R&D (12% of sales) holding operating margin near 7%. FY2023 was an outlier: the Novartis upfront flowed almost entirely to gross and operating profit (operating margin 14.8%, net income KRW 212.5 bn) and R&D expense fell as programmes matured or were capitalised. FY2024–25 show the structural problem: K-CAB's exit and Januvia generics removed high-volume products, Prolia's April 2025 patent expiry cut prices on a top-three brand, and the replacements (Godex, Fexuclue and, from Q4 2025, Wegovy) carry thin margins. Gross margin fell 8.6 percentage points in two years, and operating margin reached a five-year low of 4.8% in FY2025 even as revenue hit a record.
Quarterly run-rate (standalone, 2026)
Sources: preliminary disclosure of 31 Jul 2026 (Dailian, Dealsite, Bizwatch); Q1 derived as H1 minus Q2. DS Investment (26 May 2026) cited Q1 operating income of KRW 14.1 bn, which conflicts with the derived KRW 17.6 bn; the derived figure is consistent with the half-year disclosure. Q2 2026 operating margin was 4.2% versus 5.2% in Q2 2025.
Balance sheet
Goodwill is nil; the intangibles line consists of capitalised development costs, licences and other intangibles. Land rose from KRW 112.3 bn to KRW 214.2 bn in FY2025, reflecting the Baegot site purchase (KRW 94.9 bn).
Commentary. The FY2023 windfall turned a modest net-debt position into net cash of KRW 145 bn. That cushion has since been consumed by three forces: (1) an inventory build of KRW 114 bn in FY2024 and KRW 97 bn in FY2025 (linked to new merchandise, notably Wegovy stocking), (2) the Baegot land purchase, and (3) higher capitalised intangibles. Total debt nearly doubled in FY2025 to KRW 367.8 bn, including KRW 217.7 bn of new long-term borrowings and the exchangeable bond. By Jun-2026, S&P shows total debt of KRW 437.4 bn and net debt of KRW 108.1 bn. With KRW 392.5 bn of facility spending committed through Aug 2028 and a KRW 1 tn five-year credit framework signed with Woori Bank in May 2026, leverage will rise further.
Cash flow
Commentary. Excluding FY2023, operating cash flow has been weak relative to earnings — FY2021–25 cumulative OCF ex-FY2023 was KRW 212 bn against cumulative net income ex-FY2023 of KRW 310 bn — because working capital (inventory and receivables) has absorbed cash as the merchandise book grew. TTM to Jun-2026, OCF recovered to KRW 123.3 bn, but capex of KRW 188.7 bn pushed FCF to -KRW 65.4 bn. Shareholder returns are small (dividends ~KRW 14 bn per year at peak; the FY2025 DPS cut to KRW 500 roughly halves the cash outlay in 2026).
Ratios
S&P's own TTM figures (Oct 2026): ROE 8.2%, ROA 2.9%, ROIC 6.9%, current ratio 2.04, debt/equity 0.43, interest coverage 9.7x, asset turnover 1.06x.
Commentary. Returns have mean-reverted to high single digits after the FY2023 spike. The most concerning trend is the cash conversion cycle lengthening by nearly 40 days since FY2023, entirely through inventory, at the same time as interest-bearing debt is rising.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Pharmaceuticals segment revenue (KRW Bn) | 1,669.4 | 1,586.4 | 1,692.4 |
Segment operating income (KRW Bn) | 246.6 | 99.5 | 80.6 |
Segment operating margin (%) | 14.8 | 6.3 | 4.8 |
Segment revenue YoY growth (%) | 12.2 | -5.0 | 6.7 |
Share of total revenue (%) | 100 | 100 | 100 |
Revenue by Segment
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Standalone revenue (KRW Bn) | 1,649.6 | 1,559.3 | 1,681.2 |
Standalone operating income (KRW Bn) | 240.8 | 88.1 | 80.1 |
Consolidated revenue (KRW Bn) | 1,669.4 | 1,586.4 | 1,692.4 |
Consolidated operating income (KRW Bn) | 246.6 | 99.5 | 80.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGroup Entities
| Entity | Relationship | Role |
|---|---|---|
Chong Kun Dang Holdings Corp. (KRX: 001630) | Parent; ~39.3% with related parties | Pure holding company; chairman Lee Jang-han; CEO Choi Hee-nam |
Chong Kun Dang Pharmaceutical Corp. (185750) | Listed operating company | — |
Achella (아첼라) | Subsidiary, est. Oct 2025 | NRDO: clinical development and commercialisation of CKD-508 (now ACL-508), CKD-514, CKD-513 |
Neurateon (뉴라테온) | Subsidiary, launched 2026 | R&D specialist: formulation and technology research |
US research entity | Subsidiary | — |
PT CKD OTTO Pharmaceuticals † | Indonesian joint venture | — |
Chong Kun Dang Bio (063160), Kyongbo Pharm (214390), Chong Kun Dang Health, Chong Kun Dang Industry | Sister companies under Holdings | APIs, fermentation, health functional foods; not consolidated by 185750 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 1,343.6 | 1,488.3 | 1,669.4 | 1,586.4 | 1,692.4 |
Revenue growth YoY (%) | 3.1 | 10.8 | 12.2 | -5.0 | 6.7 |
Cost of revenue (KRW Bn) | 847.7 | 945.7 | 1,007.2 | 1,053.8 | 1,166.0 |
Gross profit (KRW Bn) | 495.8 | 542.6 | 662.2 | 532.6 | 526.4 |
SG&A (KRW Bn) | 221.0 | 237.9 | 256.6 | 267.8 | 270.6 |
R&D expense, expensed (KRW Bn) | 163.3 | 176.3 | 140.2 | 143.9 | 154.1 |
Operating income (KRW Bn) | 94.8 | 109.9 | 246.6 | 99.5 | 80.6 |
EBITDA (KRW Bn) | 112.7 | 137.6 | 287.6 | 150.1 | 125.4 |
Net income (KRW Bn) | 42.7 | 81.0 | 212.5 | 109.1 | 77.5 |
EPS basic (KRW) | 3,118 | 6,609 | 16,704 | 8,207 | 5,882 |
Gross margin (%) | 36.9 | 36.5 | 39.7 | 33.6 | 31.1 |
Operating margin (%) | 7.1 | 7.4 | 14.8 | 6.3 | 4.8 |
EBITDA margin (%) | 8.4 | 9.2 | 17.2 | 9.5 | 7.4 |
Net margin (%) | 3.2 | 5.4 | 12.7 | 6.9 | 4.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1 2026 | Q2 2026 | H1 2026 |
|---|---|---|---|
Standalone revenue (KRW Bn) | 447.7 | 475.4 | 923.1 |
Revenue YoY (%) | 12.2 | 10.7 | 11.4 |
Standalone operating income (KRW Bn) | 17.6 | 19.9 | 37.5 |
Operating income YoY (%) | 36.4 | -10.1 | 7.1 |
Standalone net income (KRW Bn) | 14.9 | 18.0 | 32.9 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | 1,046.7 | 1,124.9 | 1,402.4 | 1,458.8 | 1,800.3 |
Cash & equivalents (KRW Bn) | 131.8 | 117.4 | 219.6 | 228.5 | 216.2 |
Cash + short-term investments (KRW Bn) | 187.3 | 155.9 | 365.1 | 302.2 | 346.5 |
Accounts receivable (KRW Bn) | 203.6 | 248.4 | 269.6 | 266.7 | 265.8 |
Inventory (KRW Bn) | 224.7 | 270.1 | 261.4 | 353.8 | 428.6 |
PP&E (KRW Bn) | 298.9 | 310.7 | 319.8 | 320.8 | 437.7 |
Goodwill & intangibles (KRW Bn) | 20.8 | 27.0 | 52.1 | 74.5 | 90.0 |
Short-term debt incl. current portion & leases (KRW Bn) | 102.1 | 124.4 | 184.8 | 69.5 | 165.9 |
Long-term debt incl. leases (KRW Bn) | 135.0 | 111.3 | 35.0 | 118.7 | 201.9 |
Total debt (KRW Bn) | 237.1 | 235.7 | 219.8 | 188.2 | 367.8 |
Net debt (KRW Bn) | 49.7 | 79.9 | -145.3 | -114.0 | 21.3 |
Total liabilities (KRW Bn) | 480.9 | 503.6 | 586.8 | 562.4 | 793.9 |
Shareholders' equity (KRW Bn) | 565.8 | 621.3 | 815.6 | 896.4 | 1,006.4 |
Working capital (KRW Bn) | 346.9 | 339.4 | 435.1 | 593.6 | 575.7 |
Book value per share (KRW) | 41,433 | 46,315 | 61,049 | 67,748 | 76,180 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | 12.9 | 67.7 | 318.2 | 64.3 | 67.4 |
Capital expenditure (KRW Bn) | 48.2 | 44.9 | 41.2 | 38.5 | 140.9 |
Free cash flow (KRW Bn) | -35.3 | 22.8 | 276.9 | 25.8 | -73.6 |
Purchase of intangibles (KRW Bn) | 3.6 | 8.2 | 27.6 | 27.5 | 38.2 |
Change in inventory (KRW Bn) | -53.8 | -54.5 | -6.0 | -114.3 | -96.6 |
Dividends paid (KRW Bn) | 10.8 | 11.2 | 11.6 | 13.3 | 13.8 |
Share buybacks (KRW Bn) | 1.9 | 1.9 | 6.0 | 16.0 | 1.8 |
Net debt issued / (repaid) (KRW Bn) | 97.9 | -3.2 | -26.1 | -33.7 | 182.5 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 7.5 | 13.6 | 29.6 | 12.7 | 8.1 |
ROA (%) | 4.1 | 7.5 | 16.8 | 7.6 | 4.8 |
ROIC, after 24% notional tax (%) | 11.7 | 11.9 | 28.0 | 9.7 | 6.0 |
Current ratio (x) | 2.08 | 1.91 | 1.85 | 2.61 | 2.12 |
Debt / equity (x) | 0.42 | 0.38 | 0.27 | 0.21 | 0.37 |
Net debt / EBITDA (x) | 0.44 | 0.58 | -0.51 | -0.76 | 0.17 |
Interest coverage, EBIT / cash interest (x) | 25.2 | 17.1 | 28.6 | 13.0 | 12.9 |
Asset turnover (x) | 1.28 | 1.37 | 1.32 | 1.11 | 1.04 |
Days sales outstanding (days) | 55 | 61 | 59 | 61 | 57 |
Days inventory outstanding (days) | 97 | 104 | 95 | 123 | 134 |
Days payables outstanding (days) | 56 | 56 | 67 | 69 | 67 |
Cash conversion cycle (days) | 96 | 109 | 87 | 115 | 125 |
Capital Markets
| Item | Value | Source / date |
|---|---|---|
Share price | KRW 65,200 | 14 Oct 2026 |
52-week change | -19.2% | S&P |
YTD change | -20.5% | Paasa (mid-2026) |
5-year change | -32.7% | Paasa (mid-2026) |
52-week high (2025) | KRW ~121,100 (adjusted) | Yuanta, Jul 2025 |
200-day / 50-day MA | KRW 78,049 / 67,034 | S&P |
Beta (5Y) | 0.24 | S&P |
Trailing P/E | 11.0x | S&P |
Forward P/E | 12.8x | S&P |
EV/EBITDA | 8.0x | S&P |
EV/Sales | 0.55x | S&P |
P/B | 0.85x | S&P |
Per-Share Data and Margin Analysis (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Cash DPS (KRW) | 1,100 | 500 |
Dividend yield at payment (%) | 1.2 | 0.8 |
Stock dividend (%) | 5 | 0 |
Analyst Conclusions
Guidance and consensus
No formal guidance. Broker forecasts (Naver-hosted note, 21 Jul 2026) project standalone revenue of KRW 1.903 tn in FY2026 and KRW 1.982 tn in FY2027, with operating income of KRW 79.5 bn and KRW 89.7 bn respectively; Wegovy is forecast at about KRW 190 bn in FY2026. S&P consensus shows 3-year revenue growth of 5.5% and EPS growth of -2.9%.
Bull case
-
CKD-510 success: positive Phase 2 data in AF would trigger milestones and justify the KRW 210–240 bn rNPV estimates — roughly a quarter of the current market cap.
-
Mean-reverting valuation: at 0.85x book and 8x EV/EBITDA, the stock prices in little for the pipeline or for margin recovery.
-
Scale effect: a KRW 1.9 tn revenue base with stable SG&A could deliver operating leverage once R&D spending plateaus.
Bear case
-
Structural margin decline: merchandise growth keeps operating margin near 4–5%, below Hanmi and Daewoong.
-
Choline clawback: indication deletion would remove a top product and trigger a cash refund.
-
Capex and leverage: KRW 2.2 tn Baegot plan versus FCF that has been negative in FY2025 and TTM.
Catalysts and monitorables (next 12 months)
-
Q3 2026 results (26 Oct 2026) and FY2026 results (Feb 2027).
-
MFDS decision on choline alfoscerate indications and refund quantum.
-
Novartis disclosures on CKD-510 Phase 2.
-
CKD-703 dose-escalation data and any partnering.
-
CKD339 Phase 3 progress.
-
Wegovy share trends versus Mounjaro.
-
Baegot construction and financing.
-
CEO term expiry at the March 2027 AGM.
-
Dividend policy for FY2026.
Analyst verdict
Chong Kun Dang is a company at an awkward midpoint between two business models. As a domestic commercial platform it is arguably best in class: it replaced the loss of K-CAB, Korea's leading gastrointestinal brand, within two years and grew revenue to a record KRW 1.69 tn, and it has become the default partner for multinationals entering primary care — most recently Novo Nordisk with Wegovy and Bayer with Eylia. But that success comes at the cost of profitability. Each new co-promotion adds revenue at a thin margin, pushing gross margin down by nearly nine points in two years and operating margin to below 5%, while working capital has absorbed cash and the balance sheet has moved back into net debt.
The innovator thesis is real but narrow. CKD-510 is the only asset with external validation; its fate rests with Novartis, and its value will be determined by Phase 2 data in atrial fibrillation. CKD-703 has only just dosed its first patient. The rest of the pipeline is early, and the Achella and Neurateon structures, while sensible, have yet to prove they can attract outside capital.
Meanwhile, management has committed to the most ambitious capital programme in the company's history at the moment when cash generation is weakest and the choline alfoscerate verdict is pending. The dividend cut signals that management recognises the funding tension.
Our assessment is that the shares, at 0.85x book and roughly 11x trailing earnings, already discount much of the margin pressure, and that CKD-510 offers asymmetric upside. However, near-term earnings visibility is poor, and investors should expect the regulatory overhang (choline, price reform) and Baegot funding to dominate the next two to four quarters. We characterise the stock as a pipeline-optionality hold with a negative earnings bias, where the key swing factors are the choline decision and CKD-510 Phase 2 readout timing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Age |
|---|---|---|---|
Kim Young-joo | President & CEO, inside director | CEO since Mar 2015; reappointed Mar 2024 (term to the 2027 AGM). Microbiology degree, Korea University; MS in immunology, Long Island University; previously at Merck, credited with building its prescription business and, at CKD, with tripling revenue and securing the Novartis licence | Born 1964 (≈62) |
Lee Kyu-woong | Head of Marketing Division, inside director | Reappointed Mar 2026 | — |
Kwon Yoo-kyung | Head of Development Center, inside director | Newly appointed Mar 2026 | — |
Lee Dong-ha | Head of Planning Team, inside director | Appointed Mar 2024 | ≈52 |
Lee Mi-yeop | Head of Product Development Division | Spokesperson for CKD-510 licence (2023) | — |
Lee Chang-sik | Research Director | Leads ADC programme (CKD-703) | — |
Lee Woo-ram | Standing statutory auditor | Appointed Mar 2026; former audit partner (상무), Samil PwC | — |
“—” = not publicly disclosed.
Executive Leadership Team — Lee Jang-han
| Name | Role |
|---|---|
Lee Jang-han | Chairman, Chong Kun Dang Holdings; controlling family |
Choi Hee-nam | CEO, Chong Kun Dang Holdings (since Mar 2024); former IMF executive director and Korea Investment Corporation CEO |
Lee Hee-jae | Inside director, Holdings (ex-CJ Corp. M&A head), appointed 2024 |
Park Wan-gap | CEO, Chong Kun Dang Bio (2024) |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Chong Kun Dang Holdings + 5 related parties | ~39.3% | Kiwoom, Oct 2025 |
Foreign investors (aggregate) | ~14.2% | Kiwoom, Oct 2025 |
Minority shareholders (40,640 holders) | 32.13% | DART FY2025 |
Treasury shares | ~4.5% of issued (626,712 shares earmarked for the 2025 exchangeable bond) | Dealsite, Sep 2025; S&P share count |
Institutions (aggregate, S&P) | 28.3% | S&P, Oct 2026 |
Competitive Landscape
Peer Comparison FY2025
| Company | FY2025 revenue (KRW Bn) | FY2025 OP (KRW Bn) | OP margin (%) | Positioning vs CKD |
|---|---|---|---|---|
Yuhan Corp. | 2,186.6 | 104.4 | 4.8 | #1 traditional pharma; Leclaza (lazertinib) global royalties; similar in-licensed model |
GC Biopharma | 1,991.3 | 69.1 | 3.5 | Plasma and vaccines; Alyglo US sales USD 106 m in 2025 |
Chong Kun Dang | 1,692.4 | 80.6 | 4.8 | — |
Kwangdong Pharmaceutical | 1,659.5 | 31.0 | 1.9 | Consumer health / beverages |
Daewoong Pharmaceutical | 1,570.9 | 196.8 | 12.5 | Fexuclue, Envlo, Nabota exports; CKD partner and competitor |
Hanmi Pharmaceutical | 1,547.5 | 257.8 | 16.7 | Own-brand combinations (Rosuzet, Amosartan); highest profitability |
HK inno.N | 1,063.2 | 110.9 | 10.4 | K-CAB owner (former CKD partner) |
Boryung | 1,017.4 | 65.1 | 6.4 | Kanarb family; Bizwatch cites revenue of KRW 1,036.0 bn (discrepancy) |
Daewoong Bio | — | — | — | Gliatamin, #1 in choline alfoscerate (direct Gliatilin competitor) |
Celltrion Pharm, Dong-A ST, Jeil, Ildong | — | — | — | Cardiometabolic primary-care competitors |
Eli Lilly Korea and its Mounjaro partner | — | — | — | Direct competitor to Wegovy in obesity |
Peer Comparison FY2025 — Revenue
| Metric | Chong Kun Dang | Yuhan | Hanmi | Daewoong |
|---|---|---|---|---|
Revenue (KRW Bn) | 1,692.4 | 2,186.6 | 1,547.5 | 1,570.9 |
OP margin (%) | 4.8 | 4.8 | 16.7 | 12.5 |
Revenue growth (%) | 6.7 | — | — | — |
R&D intensity (%) | ~11 | — | — | — |



